Breaking News
1 day ago
Simantini Singh Deo
Simantini Singh Deo
Zentalis Pharmaceuticals begins dosing in DENALI Part 2 trial of azenosertib, targeting Cyclin E1+ PROC, aiming for accelerated approval if successful.
Simantini Singh Deo
Portage Biotech shares promising PORT-7 preclinical results, eyes human trials and plans PORT-6, PORT-7 combo for enhanced immunotherapy.
Simantini Singh Deo
BEYONTTRA® (acoramidis) approved in the UK for ATTR-CM, offering near-complete TTR stabilization and improved patient outcomes, based on Phase 3 study success.
Simantini Singh Deo
Beyond Air secures U.S. Patent for using gNO to treat NTM lung infections, offering a new treatment option for patients.
Simantini Singh Deo